Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Foradil Inhaler Falls Prey To Concerns About Single-Entity LABA Products

Executive Summary

Novartis Foradil Certihaler (formoterol fumarate inhalation powder) is the first victim of a recommendation by several FDA advisory committees to withdraw the asthma indication for formoterol and salmeterol
Advertisement

Related Content

Future of Skyepharma's combination asthma therapy Flutiform is up in the air in the U.S.
Future of Skyepharma's combination asthma therapy Flutiform is up in the air in the U.S.
GSK/Theravance Press On With LABA After Cmtes. Cut Asthma Indication
GSK/Theravance Press On With LABA After Cmtes. Cut Asthma Indication
Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs
Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs
GSK/Theravance Press Forward With Once-Daily LABA After FDA Vote On Asthma Class
FDA Panels Favor Advair, Symbicort Over Single-Entity LABAs For Asthma
Novartis’ Foradil Certihaler Approved For Asthma
Advertisement
UsernamePublicRestriction

Register

PS050478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel